

QUARTERLY ACTIVITIES & CASHFLOW REPORT

Highlights

- Q4 FY26 cash receipts of **\$4.0M** with **net positive operating cash inflow of \$0.7M**
- Full-year FY26 cash receipts of **\$14.3M** with **net positive operating cash inflow of \$2.9M**
- **Positive operating cash flow recorded in all four quarters of FY26**
- Cash at bank of **\$4.8M at quarter-end**, with bank debt of **\$2.5M**, representing a strong **net cash position of \$2.3M**, up from \$1.8M at 31 March 2026
- Major pharma **\$13.8M clinical trial** (announced Nov 2024) **60-patient recruitment target achieved in April 2026**, with patients progressively reaching **study completion** and triggering associated invoicing
- Continued strong **SaMD bid and tender activity**, with total forward orders and tendered pipeline **exceeding \$12M and several contracts won or extended during the quarter**
- **TrialsWest Osborne Park** consistently profitable, and **Mandurah clinic** performing ahead of expectations
- **New Non-Invasive MRI Liver Fibrosis** device EPoC trial fully recruited and data analysis underway

Resonance Health Limited (**Resonance** or **Company**) (ASX: **RHT**) is pleased to release its Appendix 4C and Quarterly Activities & Cashflow Report for the quarter and financial year ended 30 June 2026.

Operational Update

Resonance Health made significant progress in each of its three focus areas; (i) Clinical Trial Management CRO Services (**Resonance Clinical**), (ii) Software-as-a-Medical-Device Image Analysis Services (**SaMD**), and (iii) Clinical Trial Site Services (**TrialsWest**) (collectively, the **Group**).

Resonance Clinical

Recruitment for the major pharma **\$13.8M clinical trial** announced in November 2024 was completed during the quarter, with the **60-patient recruitment target achieved**. Patients are now progressively reaching study completion milestones, triggering associated invoicing events which are expected to continue during the first half of FY27. Resonance Clinical continues to bid for new work from existing and new customers, with several opportunities currently being progressed.

TrialsWest

The TrialsWest business continues to perform well, underpinned by strong demand from pharmaceutical customers. The **Osborne Park clinic** remains consistently profitable, with an annualised revenue run-rate approaching our original target capacity for the site. The **Mandurah clinic**, opened in July 2025, continues to perform ahead of expectations, with multiple trials now underway and the site achieving close to breakeven performance in its first year of operation. The TrialsWest team continues to evaluate additional locations and therapeutic areas to support further expansion.

Software-as-a-Medical Device (SaMD)

The SaMD business secured new contracts and extensions with global pharmaceutical customers during the quarter, reflecting continued strong demand for the Company's proprietary imaging analysis products and services. Total forward orders and bid (tendered) pipeline now exceed **\$12M**, with several extensions and new wins during the quarter, supporting multi-year revenue visibility. Notably, clinical trial revenue is up significantly compared to FY25.

New 'Non-Invasive MRI Liver Fibrosis' device Extended-Proof-of-Concept (EPoC) Trial

Recruitment for the EPoC Trial was completed during the quarter and data analysis is now underway, with validation to follow subject to the data analysis being successful. Data analysis is expected to be completed within the next 3 months. Subject to successful outcomes, the Company will progress regulatory planning, with one of the key first practical steps in this process involving the product being utilised by existing customers as an investigational endpoint alongside biopsy in clinical trials.

Financial Summary

Cash receipts from customers were **\$4.0M** for the quarter, with **net positive operating cash inflow of \$0.7M**. For the full year FY26, cash receipts from customers were **\$14.3M**, with **net positive operating cash inflow of \$2.9M**. The Group was **operating cash flow positive in each quarter of FY26**.

The Company closed the quarter with **\$4.8M in cash**, compared to \$4.4M at the end of the prior quarter, and **\$2.5M in bank debt** under its National Australia Bank facility, representing a **net positive cash position of \$2.3M**. In FY26, cash at bank increased by \$1.9M (from \$3.0M at 30 June 2025) while the Company repaid \$0.3M of borrowings.

Outlook

The Company continues to execute on its strategy to grow its three core business areas, supported by:

- Strong and growing **SaMD services contract pipeline**;
- Continued expansion and performance of the **TrialsWest clinic network**; and
- Ongoing execution of **clinical trial contracts by Resonance Clinical**.

With a strengthened Board, a full year of positive operating cash flow, and a growing net cash position, the Company is well placed to pursue its strategic growth initiatives in FY27.

Andrew Harrison, MD & CEO of the group noted:

"FY26 was a year of significant progress for Resonance Health, with the Group operating cash flow positive in every quarter and closing the year with a strengthened balance sheet. The completion of recruitment in our major clinical trial, a strong SaMD services order book and bid pipeline, and a growing and profitable TrialsWest clinic network, provide real momentum heading into FY27. With the recent additions to our Board and growth in net cash position, the Company is well positioned to fund and pursue its next phase of growth."

To watch Mr Harrison's video presentation, please visit the Company's InvestorHub:

<https://investors.resonancehealth.com/link/rANjxP>

Further Investor Information: <https://investors.resonancehealth.com>

This announcement has been authorised for release in accordance with the delegated authority of the Board of Directors of Resonance Health Limited.

For further information:

Andrew Harrison

Managing Director

E: andrewh@resonancehealth.com

P: +61 8 9286 5300

About Resonance Health

Resonance Health is an Australian healthcare technology and services company. The Company's services are used globally by clinicians in the management of human diseases and by pharmaceutical and therapeutic companies in their clinical trials. Resonance Health has gained endorsement by leading physicians worldwide for providing high-quality quantitative assessments essential in managing diseases and drug development.

Resonance Health's dedication to scientific rigour and quality has enabled it to achieve regulatory clearances for a range of Software-as-Medical Devices (**SaMDs**) in the USA, Europe, UK, and Australia, and to proudly carry ISO 13485 certification for the design and manufacture of medical devices. Regulatory cleared SaMD products, some of which incorporate Artificial Intelligence (**AI**), include:

- **FerriScan®**, a core-lab product that provides an accurate assessment of liver iron concentration (**LIC**) through non-invasive MRI-based technology, for use in the assessment of individuals with iron overload conditions. Internationally recognised as the gold standard in LIC assessment.
- **FerriSmart®**, an AI-trained, non-invasive MRI-based device for the automated real-time assessment of LIC in participants, calibrated against the global gold standard, FerriScan®.
- **HepaFatScan®**, an MRI-based solution which provides a reliable non-invasive assessment of liver-fat in liver tissue for use in the assessment of individuals with confirmed or suspected fatty-liver-disease.
- **HepaFatSmart®**, an AI-trained, non-invasive device for the automated real-time multi-metric assessment of liver-fat in participants, for the assessment of individuals with confirmed or suspected fatty liver disease.
- **LiverSmart®**, an AI-trained, non-invasive MRI-based multi-parametric device combining FerriSmart® and HepaFat-AI® into a consolidated report providing accurate assessment of LIC and liver fat.
- **CardiacT2***, the most widely accepted MRI method for assessing heart iron loading. Resonance Health offers a dual analysis of FerriScan® and CardiacT2*.

The Company has a development pipeline of additional medical imaging analysis products and services, including the **MRI Liver Fibrosis Project**, aimed at accurately assessing the presence and progression of liver fibrosis utilising non-invasive MRI analysis. The Company also has a clinical trials business which both manages clinical trials in Australia and includes the site management operations of TrialsWest.

Stakeholders, including clinicians, participants, and shareholders, are encouraged to register their interest at www.resonancehealth.com and to follow Resonance Health on LinkedIn.

Disclaimer Forward Looking Statements

This announcement has been prepared by Resonance Health Ltd ("Resonance Health" or "Company") and may contain forward-looking statements that are based on current expectations and beliefs and are subject to numerous factors and uncertainties that could cause actual results to differ materially from those described. Forward looking statements contained in this release may include statements about future financial and operating results, status of regulatory submissions, possible or assumed future growth opportunities and risks and uncertainties that could affect Resonance Health's products and services.

These forward-looking statements are not guarantees of future performance, involve certain risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may prove inaccurate. Actual outcomes and results may differ materially from what is expressed in any forward-looking statement in which Resonance Health expresses an expectation or belief as to future results. There can be no assurance that the statement or expectation or belief will result or be achieved or accomplished. Resonance Health will not update forward-looking statements unless required by law.

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Resonance Health Limited

ABN

96 006 762 492

Quarter ended ("current quarter")

30 June 2026

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
1. Cash flows from operating activities			
1.1 Receipts from customers		3,961	14,281
1.2 Payments for			
(a) research and development		(93)	(433)
(b) product manufacturing and operating costs			
(c) advertising and marketing		(215)	(396)
(d) leased assets			
(e) staff costs		(1,462)	(6,136)
(f) administration and corporate costs		(1,422)	(4,980)
1.3 Dividends received (see note 3)			
1.4 Interest received		6	17
1.5 Interest and other costs of finance paid		(51)	(205)
1.6 Income taxes paid		-	733
1.7 Government grants and tax incentives		-	-
1.8 Other (provide details if material)			
1.9 Net cash from / (used in) operating activities		724	2,881
2. Cash flows from investing activities			
2.1 Payments to acquire or for:			
(a) entities			
(b) businesses		-	-
(c) property, plant and equipment		(33)	(95)
(d) investments			
(e) intellectual property		(52)	(206)
(f) other non-current assets			

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
2.2	Proceeds from disposal of:		
	(a) entities		
	(b) businesses		
	(c) property, plant and equipment		
	(d) investments		
	(e) intellectual property		
	(f) other non-current assets		
2.3	Cash flows from loans to other entities		
2.4	Dividends received (see note 3)		
2.5	Other (provide details if material)		
2.6	Net cash from / (used in) investing activities	(85)	(301)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities		
3.3	Proceeds from exercise of options		
3.4	Transaction costs related to issues of equity securities or convertible debt securities		
3.5	Proceeds from borrowings		
3.6	Repayment of borrowings	(80)	(320)
3.7	Transaction costs related to loans and borrowings		
3.8	Dividends paid		
3.9	Other:		
	- Lease payments	(71)	(309)
	- Net payments for cash backed guarantees	-	32
3.10	Net cash from / (used in) financing activities	(151)	(598)

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,387	2,977
4.2	Net cash from / (used in) operating activities (item 1.9 above)	724	2,881

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (12 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(86)	(301)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(152)	(598)
4.5	Effect of movement in exchange rates on cash held	(24)	(110)
4.6	Cash and cash equivalents at end of period	4,849	4,849

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	4,849	4,387
5.2	Call deposits	-	-
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	4,849	4,387

6.	Payments to related parties of the entity and their associates	Current quarter \$A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	233
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Appendix 4C
Quarterly cash flow report for entities subject to Listing Rule 4.7B

7.	Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity.</i> <i>Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1	Loan facilities	2,533	2,533
7.2	Credit standby arrangements		
7.3	Other (please specify)		
7.4	Total financing facilities	2,533	2,533
7.5	Unused financing facilities available at quarter end		NIL
7.6	Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	Secured Financing Facility from National Australia Bank, facility expiry date is 31 March 2027. Interest rate is BBSY + 2.5% per annum.		

8.	Estimated cash available for future operating activities	\$A'000
8.1	Net cash from / (used in) operating activities (item 1.9)	724
8.2	Cash and cash equivalents at quarter end (item 4.6)	4,849
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	4,849
8.5	Estimated quarters of funding available (item 8.4 divided by item 8.1)	N/A
	<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6	If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
	8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not? Answer: N/A	
	8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful? Answer: N/A	
	8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis? Answer: N/A	
	<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 24 July 2026

Authorised by: By the Board of Directors of Resonance Health Limited

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.